PDF herunterladen
Synlett 2010(3): 457-461  
DOI: 10.1055/s-0029-1219191
LETTER
© Georg Thieme Verlag Stuttgart ˙ New York

Stereoselective Total Synthesis of (-)-Ovalicin

J. S. Yadav*, P. Narayana Reddy, B. V. Subba Reddy
Division of Organic Chemistry I, Indian Institute of Chemical Technology, Hyderabad 500007, India
Fax: +91(40)27160512; e-Mail: yadavpub@iict.res.in;
Weitere Informationen

Publikationsverlauf

Received 28 August 2009
Publikationsdatum:
11. Januar 2010 (online)

    Lizenzen und Reprints Alle Artikel dieser Rubrik

Abstract

A new synthetic route for epoxyketone 3 is described, which is a key intermediate in Barton’s synthesis of ovalicin (1), a powerful anti-angiogenetic inhibitor, from commercially available d-ribose. The key reactions involved in this synthesis are ring-closing metathesis, Rubottom oxidation and Corey-Chaykovsky epoxidation. The subsequent transformations are carried out according to Barton’s strategy to complete the total synthesis of (-)-ovalicin.

Keywords

ribose - Rubottom oxidation - ring-closing metathesis - Corey-Chaykovsky epoxidation

    References and Notes

  • 1a Sigg HP. Weber HP. Helv. Chim. Acta  1968,  51:  1395 
    Google Scholar
  • 1b Bollinger P. Sigg HP. Weber HP. Helv. Chim. Acta  1973,  56:  819 
    Google Scholar
  • 2 Griffith EC. Su Z. Niwayama S. Ramsay CA. Chang Y.-H. Liu JO. Proc. Natl. Acad. Sci. U.S.A.  1998,  95:  15183 
    CrossrefPubMedGoogle Scholar
  • 3 Zimmermann WA. Hartmann GR. Eur. J. Biochem.  1981,  118:  143 
    CrossrefPubMedGoogle Scholar
  • 4 Ingber D. Fujita T. Kishimoto S. Sudo K. Kanamaru T. Brem H. Folkman J. Nature (London)  1990,  348:  555 
    CrossrefPubMedGoogle Scholar
  • 5 Borel JF. Lazary S. Staehelin H. Agents Actions  1974,  4:  357 
    CrossrefPubMedGoogle Scholar
  • 6a Corey EJ. Dittami JP. J. Am. Chem. Soc.  1985,  107:  256 
    Google Scholar
  • 6b Corey EJ. Guzman-Perez A. Noe MC. J. Am. Chem. Soc.  1994,  116:  12109 
    Google Scholar
  • 6c Barton DHR. Bath S. Billington DD. Gero SD. Quiclet-Sire B. Samadi M. Org. Bioorg. Chem.  1995,  12:  1551 
    Google Scholar
  • 6d Barco A. Benetti S. De Risi C. Marchetti P. Pollini GP. Zanirato V. Tetrahedron: Asymmetry  1998,  9:  2857 
    Google Scholar
  • 7a Yamaguchi J. Toyoshima M. Shoji M. Kakeya H. Osada H. Hayashi Y. Angew. Chem. Int. Ed.  2006,  45:  789 
    Google Scholar
  • 7b Takahashi S. Hishinuma N. Koshino H. Nakata T. J. Org. Chem.  2005,  70:  10162 
    Google Scholar
  • 7c Tiefenbacher K. Arion VB. Mulzer J. Angew. Chem. Int. Ed.  2007,  46:  2690 
    Google Scholar
  • 7d Yadav JS. Sreedhar P. Dinesh CB. Srihari P. Synlett  2007,  992 
    Google Scholar
  • 7e Hua H. Zhao H. Battina K. Lou K. Jimenez L. Desper J. Perchellet M. Perchellet H. Chaiang K. Bioorg. Med. Chem.  2008,  16:  5232 
    Google Scholar
  • 8 Leonard NJ. Carraway KL. J. Heterocycl. Chem.  1966,  3:  485 
    CrossrefGoogle Scholar
  • 9 Garegg PJ. Samuelson B. J. Chem. Soc., Perkin Trans. 1  1980,  2866 
    CrossrefGoogle Scholar
  • 10 Hyldtoft L. Madsen R. J. Am. Chem. Soc.  2000,  122:  8444 
    CrossrefGoogle Scholar
  • 11a Armstrong SK. J. Chem. Soc., Perkin Trans. 1  1998,  371 
    Google Scholar
  • 11b Grubbs RH. Chang S. Tetrahedron  1998,  54:  4413 
    Google Scholar
  • 11c Schuster M. Blechert S. Angew. Chem., Int. Ed. Engl.  1997,  36:  2036 
    Google Scholar
  • 11d Furstner A. Angew. Chem. Int. Ed.  2000,  39:  3013 
    Google Scholar
  • 12a Rubottom GM. Vazquez MA. Pellagrina DR. Tetrahedron Lett.  1974,  4319 
    Google Scholar
  • 12b Rubottom GM. Gruber JM. Juve HD. Charleson DA. Org. Synth.  1986,  64:  118 
    Google Scholar
  • 12c Hassner A. Reuss RH. Pinnick HW. J. Org. Chem.  1975,  40:  3427 
    Google Scholar
  • 12d Brook AG. Macrae DM. J. Organomet. Chem.  1974,  77:  C19 
    Google Scholar
  • 13 Corey EJ. Kang J. Kyler K. Tetrahedron Lett.  1985,  26:  555 
    CrossrefGoogle Scholar
  • 14 Pine SH. Shen GS. Hoang H. Synthesis  1991,  165 
    Artikel in Thieme ConnectGoogle Scholar
  • 15 Yan T.-H. Tsai C.-C. Chien C.-T. Cho C.-C. Huang P.-C. Org. Lett.  2004,  6:  4961 
    CrossrefPubMedGoogle Scholar
  • 16a Corey EJ. Chakovsky M. J. Am. Chem. Soc.  1965,  87:  1353 
    Google Scholar
  • 16b Harwood LM. Casy G. Sherlock J. Synth. Commun.  1990,  1287 
    Google Scholar
  • 17a Rodeschini V. Boiteau JG. Weghe PV. Tarnus C. Eustache J. J. Org. Chem.  2004,  69:  357 
    Google Scholar
  • 17b Boiteau JG. Weghe PV. Eustache J. Org. Lett.  2001,  3:  2737 
    Google Scholar
  • 17c Mazitschek R. Huwe A. Giannis A. Org. Biomol. Chem.  2005,  3:  2150 
    Google Scholar
  • 17d Tabber DF. Christos TE. Rheingold AL. Guzei A. J. Am. Chem. Soc.  1999,  121:  5589 
    Google Scholar
  • 18a Kishi Y. Fukuyama T. Natatsuka S. J. Am. Chem. Soc.  1973,  95:  6490 
    Google Scholar
  • 18b Fukuyama T. Natatsuka S. Kishi Y. Tetrahedron  1981,  37:  2045 
    Google Scholar
  • 18c Wu Z. Williams LJ. Danishefsky SJ. Angew. Chem.  2000,  39:  3866 
    Google Scholar
  • 18d Smith AB. Dorsey BD. Visnick M. Maeda T. Malamas MS. J. Am. Chem. Soc.  1986,  108:  3110 
    Google Scholar
19

Spectroscopic Data for Selected Products:
(3a S ,7a R )-2,2-Dimethyl-3a,4,5,7a-tetrahydro-1,3-benzodioxol-4-ol (8): major isomer, brown solid; mp 88-
90 ˚C; [α]D -18.1 (c = 1, CHCl3). IR (neat): 3440, 2923, 1648, 1373, 1075 cm-¹. ¹H NMR (300 MHz, CDCl3): δ = 1.37 (s, 3 H), 1.40 (s, 3 H), 1.96 (d, J = 8.7 Hz, 1 H), 2.25 (m, 2 H), 3.83 (m, 1 H), 4.34 (m, 1 H), 4.56 (s, 1 H), 5.69 (m, 2 H). ¹³C NMR (75 MHz, CDCl3): δ = 126.6, 126.0, 109.4, 76.1, 73.4, 67.1, 28.7, 27.3, 26.3. MS (ESI): m/z = 193 [M + Na]+.
(3a S ,7a R )-2,2-Dimethylperhydro-1,3-benzodioxol-4-ol (9): mixture of isomers, yellow oil; [α]D -26.6 (c = 1, CHCl3). IR (neat): 3446, 2937, 1376, 1032, 876 cm-¹. ¹H NMR (300 MHz, CDCl3): δ = 1.35 (s, 3 H), 1.50 (s, 3 H), 1.54-1.80 (m, 6 H), 2.07 (s, 1 H), 3.68-3.76 (m, 1 H), 4.14-4.22 (m, 2 H). ¹³C NMR (75 MHz, CDCl3): δ = 108.5, 81.5, 75.7, 74.4, 72.6, 68.2, 30.4, 28.3, 27.6, 27.5, 27.0, 26.7, 26.2, 25.6, 18.6, 17.4. MS (ESI): m/z = 195 [M + Na]+.
(3a R,7a R )-2,2-Dimethylperhydro-1,3-benzodioxol-4-one (10): white solid; mp 112-114 ˚C; [α]D -63.2 (c = 1, CHCl3). IR (neat): 3447, 2937, 1726, 1376, 1220 cm-¹. ¹H NMR (200 MHz, CDCl3): δ = 1.36 (s, 3 H), 1.41 (s, 3 H), 1.82-2.06 (m, 3 H), 2.14-2.38 (m, 2 H), 2.43-2.56 (m, 1 H), 4.22 (d, J = 5.4 Hz, 1 H), 4.53-4.61 (m, 1 H). ¹³C NMR (75 MHz, CDCl3): δ = 208.4, 109.4, 79.1, 39.9, 26.9, 26.7, 25.8, 20.2, 17.4. MS (ESI): m/z = 171 [M + H]+.
(3a R ,5 R ,7a R )-5-[1-( tert -Butyl)-1,1-diphenylsilyl]oxy-2,2-dimethylperhydro-1,3-benzodioxol-4-one (13): colorless liquid; [α]D -62.4 (c = 1.7, CHCl3). ¹H NMR (300 MHz, CDCl3): δ = 1.08 (s, 9 H), 1.36 (s, 3 H), 1.37 (s, 3 H), 1.73-1.92 (m, 2 H), 1.95-2.05 (m, 1 H), 2.41-2.55 (m, 1 H), 4.18 (dd, J = 2.2, 3.7 Hz, 1 H), 4.61 (m, 1 H), 4.82 (d, J = 5.2 Hz, 1 H), 7.31-7.46 (m, 6 H), 7.50-7.54 (m, 2 H), 7.58-7.62 (m, 2 H). ¹³C NMR (75 MHz, CDCl3): δ = 206.4, 135.5, 135.4, 134.7, 132.9, 130.1, 129.5, 127.8, 127.6, 109.6, 78.5, 77.8, 76.3, 29.2, 26.9, 26.8, 26.5, 26.1, 20.6. MS (ESI): m/z = 447 [M + Na]+.
(7 R ,8 R ,11 R )-11-[1-( tert -Butyl)-1,1-diphenylsilyl]oxy-1,5-dithiaspiro[5.5]undecane-7,8-diol (14): semi solid; [α]D +16.7 (c = 1.3, CHCl3). IR (neat): 3446, 2925, 2854, 1109, 702 cm-¹. ¹H NMR (200 MHz, CDCl3): δ = 1.09 (s, 9 H), 1.32-2.16 (m, 7 H), 2.56-2.70 (m, 1 H), 2.75-2.89 (m, 2 H), 2.92-3.11 (m, 2 H), 3.91 (dd, J = 3.8 Hz, 1 H), 4.08-4.22 (m, 2 H), 7.28-7.47 (m, 6 H), 7.65-7.81 (m, 4 H). ¹³C NMR (75 MHz, CDCl3): δ = 136.5, 135.5, 132.7, 132.2, 130.1, 129.6, 127.8, 127.4, 75.0, 74.4, 73.1, 29.6, 29.2, 27.2, 26.8, 23.3, 19.2. MS (ESI): m/z = 497 [M + Na]+.
(7 R ,8 R ,11 R )-7-(Acetyloxy)-11-[1-( tert -butyl)-1,1-diphenylsilyl]oxy-1,5-dithiaspiro[5.5]undec-8-yl Acetate (15): semi solid; [α]D +25.2 (c = 1, MeOH). IR (neat): 3451, 2929, 2856, 1743, 1245, 703 cm-¹. ¹H NMR (300 MHz, CDCl3): δ = 1.10 (s, 9 H), 1.24-1.61 (m, 5 H), 1.93 (s, 3 H), 1.96 (s, 3 H), 2.02-2.16 (m, 1 H), 2.50-2.60 (m, 1 H), 2.74-2.84 (m, 1 H), 2.98-3.10 (m, 1 H), 3.14-3.26 (m, 1 H), 3.88 (dd, J = 4.5, 12.0 Hz, 1 H), 5.53-5.62 (m, 1 H), 5.77 (d, J = 1.5 Hz, 1 H), 7.31-7.41 (m, 6 H), 7.68-7.73 (m, 2 H), 7.76-7.81 (m, 2 H). ¹³C NMR (75 MHz, CDCl3): δ = 136.3, 136.0, 135.2, 134.7, 129.6, 129.4, 127.5, 127.3, 73.4, 69.1, 60.5, 26.9, 26.5, 25.6, 24.8, 23.5, 20.8, 20.6, 19.6, 18.9. MS (ESI): m/z = 581 [M + Na]+.
(7 R ,8 R )-7-(Acetyloxy)-11-oxo-1,5-dithiaspiro[5.5]undec-8-yl Acetate (17): white solid; mp 82-84 ˚C; [α]D +163.1
(c = 1, CHCl3). IR (neat): 2924, 2854, 1747, 1236, 721 cm-¹. ¹H NMR (200 MHz, CDCl3): δ = 1.95-2.07 (m, 6 H), 2.11 (s, 3 H), 2.13-2.31 (m, 1 H), 2.41-2.55 (m, 1 H), 2.66-2.84 (m, 2 H), 2.91-3.24 (m, 3 H), 5.72-5.83 (m, 2 H). ¹³C NMR (75 MHz, CDCl3): δ = 200.9, 170.0, 169.5, 73.9, 67.5, 59.6, 33.8, 26.9, 26.4, 24.6, 24.0, 20.7, 20.4. MS (ESI): m/z = 319 [M + H]+.
(10 R,11 R )-10,11-Dihydroxy-1,5-dithiaspiro[5.5]undecan-7-one (18): white solid; mp 101-103 ˚C; [α]D +145.9 (c = 1, CHCl3). IR (neat): 3446, 2924, 1705, 1219, 771 cm-¹. ¹H NMR (300 MHz, CDCl3): δ = 1.25 (s, 1 H), 1.52-1.69 (m, 1 H), 1.76-1.93 (m, 1 H), 2.03-2.26 (m, 2 H), 2.34-2.44 (m, 1 H), 2.60-2.70 (m, 3 H), 2.87-3.03 (m, 1 H), 3.18-3.32 (m, 1 H), 3.52 (d, J = 9.0 Hz, 1 H), 3.70-3.81 (m, 1 H), 4.08-4.18 (m, 1 H). ¹³C NMR (75 MHz, CDCl3): δ = 202.7, 78.9, 68.4, 67.0, 33.3, 27.3, 26.9, 26.1, 24.2. MS (ESI): m/z = 257 [M + Na]+.
(10 R,11 R )-10-[1-( tert -Butyl)-1,1-dimethylsilyl]oxy-11-hydroxy-1,5-dithiaspiro[5.5]undecan-7-one (19): semi solid; [α]D +93 (c = 1.25, CHCl3). IR (neat): 3504, 2928, 2855, 1709, 1109, 837 cm-¹. ¹H NMR (300 MHz, CDCl3):
δ = 0.12 (s, 3 H), 0.15 (s, 3 H), 0.92 (s, 9 H), 1.42 (s, 1 H), 1.74-1.93 (m, 2 H), 2.01-2.21 (m, 2 H), 2.54-2.68 (m, 3 H), 2.87-3.00 (m, 2 H), 3.26-3.38 (m, 1 H), 3.97 (d, J = 2.2 Hz, 1 H), 4.35-4.42 (m, 1 H). ¹³C NMR (75 MHz, CDCl3): δ = 207.2, 78.2, 77.7, 75.6, 30.8, 29.4, 27.0, 26.1, 25.5, 20.4, 17.9, -5.12, -5.17. MS (ESI): m/z = 371 [M + Na]+.
tert -Butyl[(3 S ,10 R ,11 R )-10-methoxy-1-oxa-5,9-dithiadispiro[2.0.5.4]tridec-11-yl]oxydimethylsilane (21): yellow oil; [α]D -21.9 (c = 0.35, CHCl3). IR (neat): 3373, 2922, 2853, 2365, 1466, 756 cm-¹. ¹H NMR (200 MHz, CDCl3): δ = 0.09 (s, 3 H), 0.10 (s, 3 H), 0.90 (s, 9 H), 1.53-2.19 (m, 5 H), 2.37-2.74 (m, 4 H), 3.21-3.40 (m, 2 H), 3.42-3.54 (m, 2 H), 3.56 (s, 3 H), 4.17-4.29 (m, 1 H). ¹³C NMR (75 MHz, CDCl3): δ = 88.6, 83.0, 71.3, 69.8, 52.7, 32.0, 31.1, 30.6, 29.6, 29.3, 28.1, 27.4, 25.8, 24.5, -4.7.
MS (ESI): m/z = 399 [M + Na]+.
(3 S ,5 R ,6 R )-6-[1-( tert -Butyl)-1,1-dimethylsilyl]oxy-5-methoxy-1-oxaspiro [2.5]octan-4-one (3): yellow oil; [α]D -1.20 (c = 1, CH2Cl2). IR (neat): 2922, 2852, 1737, 1461, 762 cm-¹. ¹H NMR (200 MHz, CDCl3) : δ = 0.07 (s, 3 H), 0.08 (s, 3 H), 0.92 (s, 9 H), 1.40-1.60 (m, 1 H), 2.00-2.20 (m, 2 H), 2.40-2.60 (m, 1 H), 2.77 (d, J = 4.7 Hz, 1 H), 3.29 (d, J = 4.7 Hz, 1 H), 3.44 (s, 3 H), 3.98 (d, J = 2.5 Hz, 1 H), 4.44 (m, 1 H). ¹³C NMR (75 MHz, CDCl3): δ = 202.4, 87.5, 72.3, 60.7, 58.5, 51.4, 28.9, 27.1, 25.9, 18.3, -4.4, -5.0. MS (ESI): m/z = 309 [M + Na]+.
(-)-Ovalicin (1): white solid; mp 94-95 ˚C; [α]D -112 (c = 0.2, CHCl3). IR (neat): 3438, 2923, 2853, 1728, 1627, 1459, 1216, 761 cm-¹. ¹H NMR (500 MHz, CDCl3): δ = 1.37 (s, 3 H), 1.41-1.45 (m, 1 H), 1.66 (s, 3 H), 1.75 (s, 3 H), 2.12-2.18 (m, 1 H), 2.30-2.45 (m, 2 H), 2.61-2.71 (m, 2 H), 2.73 (d, J = 4.2 Hz, 1 H), 2.90 (t, J = 6.3 Hz, 1 H), 3.10 (d, J = 4.2 Hz, 1 H), 3.14 (s, 1 H), 3.57 (s, 3 H), 4.23 (s, 1 H), 5.18 (t, J = 6.6 Hz, 1 H). ¹³C NMR (75 MHz, CDCl3): δ = 206.8, 135.7, 118.2, 86.3, 78.8, 60.7, 60.5, 59.5, 57.0, 51.5, 36.9, 30.5, 27.2, 25.9, 18.2, 14.6. MS (ESI): m/z = 319 [M + Na]+.